Global Botanical Drug Market Growth (Status and Outlook) 2025-2031

The global Botanical Drug market size is predicted to grow from US$ 38940 million in 2025 to US$ 52060 million in 2031; it is expected to grow at a CAGR of 5.0% from 2025 to 2031.

A botanical drug product is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans.

A botanical drug product consists of vegetable materials, which may include plant materials, algae, macroscopic fungi, or combinations thereof.

A botanical drug product may be available as (but not limited to) a solution, powder, tablet, capsule, elixir, topical, or injection.

Botanical drug products often have unique features, for example, complex mixtures, lack of a distinct active ingredient, and substantial prior human use. Fermentation products and highly purified or chemically modified botanical substances are not considered botanical drug products.

Global 5 largest manufacturers of Botanical Drug are Buchang Pharmaceuticals, China TCM, Tsumura, Schwabe and Tong Ren Tang, which make up about 30%.

China is the largest market, with a share over 60%. In terms of product type, OTC occupy the largest share of the total market, over 60%. And in terms of application, the largest application is Cardiovascular, followed by Respiratory System and Tumor.

LPI (LP Information)' newest research report, the “Botanical Drug Industry Forecast” looks at past sales and reviews total world Botanical Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Botanical Drug sales for 2025 through 2031. With Botanical Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Botanical Drug industry.

This Insight Report provides a comprehensive analysis of the global Botanical Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Botanical Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Botanical Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Botanical Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Botanical Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Botanical Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
Prescription Drug
OTC

Segmentation by Application:
Cardiovascular
Tumor
Respiratory System
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Buchang Pharmaceuticals
China TCM
Tsumura
Schwabe
Tong Ren Tang
Jumpcan Pharmaceutical
Guangzhou Baiyunshan Pharmaceutical
Yunnan Baiyao
Tasly Holding Group
Bionorica Se
Huarun 999
Taiji
Weleda
Kwangdong
GW Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.